Results 81 to 90 of about 14,556 (187)

What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi‐Center Discrete Choice Experiment

Health Expectations, Volume 29, Issue 4, August 2026.
ABSTRACT Introduction Reimbursement decisions for orphan drugs are complex, as conventional cost‐effectiveness frameworks may not fully capture broader societal values. To investigate public preferences regarding the inclusion of rare disease drugs in China's Basic Medical Insurance (BMI) using a multi‐center discrete choice experiment.
Ya'nan Wu, Jingdan Chen, Jiachen Shao, Hui Peng, Linkang Li, Gang Chen, Shunping Li   +6 more
wiley   +1 more source

Cost-effectiveness of Kang Ai injection plus chemotherapy vs. Shenqi Fuzheng injection plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer

Frontiers in Medicine
ObjectiveThis study aimed to evaluate the cost-effectiveness of two Chinese patent medicines, including Kang Ai injection and Shenqi Fuzheng injection with each combined with platinum-based chemotherapy as the first-line treatment for patients with ...
Junjie Zhu, Junjie Zhu, Lei Tian, Lei Tian   +3 more
doaj   +1 more source

Pharmaco-Economics of Aspirin Therapy

Pakistan Armed Forces Medical Journal, 2005
Aspirin as an antiplatelet agent is the most commonly used drug in therapeutics. It is inexpensive while on the contrary other antiplatelet drugs are very expensive.
Mahmud Ahmad Akhtar
doaj  

Anaesthesia pharmacoeconomics [PDF]

Canadian Journal of Anaesthesia, 1993
openaire   +2 more sources

Analysis of the knowledge and skills of physiotherapists and physiotherapy students regarding pulmonary rehabilitation in post-COVID-19 patients

BMC Medical Education
Background Pulmonary rehabilitation plays a crucial role in the recovery of patients after COVID-19. Because training standards and clinical exposure differ internationally, the present findings should be interpreted within the Polish educational and ...
Dorota Kopciuch, Krzysztof Ciosek, Kinga Adamska, Natalia Chojara, Anna Paczkowska, Tomasz Zaprutko, Piotr Ratajczak, Elżbieta Nowakowska, Krzysztof Kus   +8 more
doaj   +1 more source

Pharmacoeconomic

Bulletin of Faculty of Pharmacy Cairo University, 2014
Community-acquired pneumonia (CAP) is a serious and widespread infection due to its high incidence, morbidity, mortality and increased healthcare costs. This study aimed at investigating antibiotic combination regimen containing fluoroquinolone (Group A) and antibiotic combination regimen not containing fluoroquinolone (Group B) in terms of ...
Weiam A. Harwan, Maggie M. Abbassi, May M. El-Attar, Samar F. Farid   +3 more
openaire   +1 more source

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

BMC Cancer
Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang   +4 more
doaj   +1 more source

Pharmacoeconomics [PDF]

Journal of Korean Society for Clinical Pharmacology and Therapeutics, 2008
openaire   +2 more sources

Correction: Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis. [PDF]

Pharmacoecon Open
Scavina M, Posner N, Dorling P, Talaga A, Stachel A, Alvir J.   +5 more
europepmc   +1 more source

Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [PDF]

Pharmacoecon Open
Rodríguez-Lago I, Peinado-Fabregat JI, Guigini M, Cerezales M, Ibáñez F, Crespo C, Barreiro-de Acosta M.   +6 more
europepmc   +1 more source